Mantovani G, Macciò A, Lai P, Ghiani M, Turnu E, Del Giacco G S
Department of Medical Oncology, University of Cagliari, Italy.
Cell Biophys. 1995 Aug;27(1):1-14. doi: 10.1007/BF02822523.
The present study investigated the peripheral blood mononuclear cells (PBMC) blastic responses to PHA, PHA plus recombinant IL-2 (rIL-2) and rIL-2 alone; the expression of membrane-bound IL-2R on PHA-stimulated PBMC; and the levels of IL-1 alpha, IL-2, IL-6, and sIL-2R in serum and in culture supernatants from PHA-stimulated PBMC in 17 patients with with non-Hodgkin's lymphoma (NHL), 4 with Hodgkin's lymphoma (HL), 5 with Hairy cell leukemia, 1 with chronic myelogenous leukemia, and 1 with chronic lymphocytic leukemia. The patients with HL and NHL with active disease (AD) were separated from those in clinical remission. The patients with AD were studied at diagnosis (obviously before therapy) and the patients in clinical remission were out of therapy since at least 6 mo. The lymphocyte blastogenic response to PHA was significantly lower in patients with HL and NHL with AD than in the control group. The response to rIL-2 alone was in the same range in the control group and in HL and NHL AD patients. By adding rIL-2 to PHA there was an increase of the blastogenic response of the same patients. The percentage of CD25 expressed on PHA-stimulated lymphocytes from patients with HL and NHL AD and from normal subjects is in the same range. Serum levels of IL-2, IL-6, and sIL-2R were significantly higher in HL and NHL AD patients than in controls as well as in all other hematological malignancies. Supernatants derived from PHA-stimulated PBMC were assessed for the presence of cytokines and sIL-2R by ELISA. The levels of IL-2, IL-6, and sIL-2R were significantly lower in HL and NHL AD patients than in controls as well as in all other hematological malignancies.
本研究调查了外周血单个核细胞（PBMC）对PHA、PHA加重组白细胞介素-2（rIL-2）以及单独rIL-2的增殖反应；PHA刺激的PBMC上膜结合白细胞介素-2受体（IL-2R）的表达；以及17例非霍奇金淋巴瘤（NHL）患者、4例霍奇金淋巴瘤（HL）患者、5例毛细胞白血病患者、1例慢性粒细胞白血病患者和1例慢性淋巴细胞白血病患者血清及PHA刺激的PBMC培养上清液中白细胞介素-1α（IL-1α）、白细胞介素-2（IL-2）、白细胞介素-6（IL-6）和可溶性白细胞介素-2受体（sIL-2R）的水平。HL和NHL活动期疾病（AD）患者与临床缓解期患者分开。AD患者在诊断时（显然在治疗前）进行研究，临床缓解期患者至少已停止治疗6个月。HL和NHL AD患者对PHA的淋巴细胞增殖反应明显低于对照组。单独对rIL-2的反应在对照组以及HL和NHL AD患者中处于相同范围。向PHA中添加rIL-2后，同一患者的增殖反应增加。HL和NHL AD患者以及正常受试者PHA刺激的淋巴细胞上表达的CD25百分比处于相同范围。HL和NHL AD患者血清中IL-2、IL-6和sIL-2R水平明显高于对照组以及所有其他血液系统恶性肿瘤患者。通过ELISA评估PHA刺激的PBMC培养上清液中细胞因子和sIL-2R的存在情况。HL和NHL AD患者中IL-2、IL-6和sIL-2R水平明显低于对照组以及所有其他血液系统恶性肿瘤患者。
